Replimune Group Inc. has amended its existing loan agreement with Hercules Capital, Inc. Under the revised terms, Replimune drew down $35 million upon closing, with the option to access an additional $120 million contingent on achieving post-approval milestones. The amendment also extends the debt repayment period from 2026 to 2027, providing Replimune with greater financial flexibility as it prepares for the potential commercialization of RP1. The company expects that this financing, alongside existing cash resources, will extend its cash runway into the first quarter of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-009510), on February 03, 2026, and is solely responsible for the information contained therein.
Comments